NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

In these patients, adding tremelimumab to durvalumab and chemotherapy resulted in higher overall response rates (42.9%) relative to patients who received durvalumab plus chemotherapy (30.2% ...

While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

NPPA directs manufacturers to reduce MRP of anti-cancer drugs following government's tax exemptions and duty reductions.

In these patients, adding tremelimumab to durvalumab and chemotherapy resulted in higher overall response rates (42.9%) relative to patients who received durvalumab plus chemotherapy (30.2%) or ...

In these patients, adding tremelimumab to durvalumab and chemotherapy resulted in higher overall response rates (42.9%) relative to patients who received durvalumab plus chemotherapy (30.2% ...

Treatment arms included standard chemotherapy alone, chemotherapy plus programmed death ligand 1 (PD-L1) inhibitor durvalumab, and chemotherapy plus durvalumab and cytotoxic T-lymphocyte ...

NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...

The government of India has mandated companies to reduce the prices of three anti-cancer drugs, Trastuzumab, Osimertinib, and ...

New Delhi- The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of ...